¶¶Òõapp¹ÙÍø researchers and start-ups have won 4 out of 6 awards at the prestigious .
won Company of the Year for its development of the innovative High-Density Microarray Patch, a needle-free vaccine delivery platform. The technology has the potential to transform vaccine delivery globally and strengthen Queensland’s position as a leader in biotechnology.
Another UniQuest start-up received the LSQ Radium Capital Emerging Innovator Award, in recognition of their work to develop new vaccines for life-threatening respiratory viral infectious diseases using ¶¶Òõapp¹ÙÍø’s Molecular Clamp platform.
¶¶Òõapp¹ÙÍø Vice-Chancellor Professor Deborah Terry said the result highlights the significant impact of the commercially relevant research being undertaken at the University.
“The success of these start-ups, build on ¶¶Òõapp¹ÙÍø innovation, is a great demonstration of research and innovation, from discovery through to translation, to solve key health challenges,” she said.
“Bringing these technologies and products to market also helps to drive Queensland’s reputation as innovation and entrepreneurship hub.”
was awarded the LSQ McCullough Robertson Industry Excellence Award in recognition of his significant contribution to the Queensland life sciences industry over his 30-year career.
Dr Smythe was involved in the discovery and translation of the anti-flu drug Relenza. In 2022, he became the CEO of , a start-up company leading the development of first-in-class pharmaceuticals to treat cardiovascular disease.
was awarded the Rose-Anne Kelso Commemorative Award for her research focused on improving cardiovascular health in under-represented communities including women and people from culturally and linguistically diverse communities.
Dr Shah is the fourth ¶¶Òõapp¹ÙÍø researcher in a row to win the Rose-Anne Kelso Award.
Other ¶¶Òõapp¹ÙÍø finalists in the 2023 LSQ awards included , and .
Media: ¶¶Òõapp¹ÙÍø Communications, communications@uq.edu.au; +61 429 056 139